Wealthcare Advisory Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Wealthcare Advisory Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.3M	Sell	4,627 -215	-4%	-$95.3K	0.04%	327
2026 Q1	$2.16M	Sell	4,842 -417	-8%	-$194K	0.04%	352
2025 Q4	$2.38M	Buy	5,259 +130	+3%	+$56K	0.05%	315
2025 Q3	$2.01M	Buy	5,129 +1,967	+62%	+$822K	0.04%	344
2025 Q2	$1.41M	Sell	3,162 -29	-0.9%	-$13.4K	0.03%	409
2025 Q1	$1.55M	Sell	3,191 -70	-2%	-$32.6K	0.04%	350
2024 Q4	$1.31M	Buy	3,261 +172	+6%	+$79.7K	0.04%	365
2024 Q3	$1.44M	Sell	3,089 -239	-7%	-$115K	0.04%	332
2024 Q2	$1.56M	Buy	3,328 +110	+3%	+$47.7K	0.05%	285
2024 Q1	$1.35M	Buy	3,218 +141	+5%	+$59.6K	0.04%	304
2023 Q4	$1.25M	Sell	3,077 -41	-1%	-$15.1K	0.05%	271
2023 Q3	$1.08M	Sell	3,118 -33	-1%	-$11.5K	0.05%	264
2023 Q2	$1.11M	Sell	3,151 -208	-6%	-$70.1K	0.05%	267
2023 Q1	$1.06M	Sell	3,359 -91	-3%	-$27.3K	0.05%	279
2022 Q4	$996K	Buy	3,450 +91	+3%	+$27.7K	0.05%	276
2022 Q3	$973K	Buy	3,359 +156	+5%	+$44.9K	0.06%	242
2022 Q2	$903K	Sell	3,203 -281	-8%	-$75.2K	0.05%	221
2022 Q1	$909K	Sell	3,484 -141	-4%	-$33.5K	0.06%	210
2021 Q4	$796K	Buy	3,625 +2,185	+152%	+$425K	0.05%	232
2021 Q3	$261K	Buy	1,440 +6	+0.4%	+$1.17K	0.02%	455
2021 Q2	$289K	Buy	1,434 +33	+2%	+$6.9K	0.02%	436
2021 Q1	$301K	Buy	+1,401	New	+$308K	0.02%	395
2020 Q2	–	Sell	-107	Closed	-$25K	–	1336
2020 Q1	$25K	Buy	107 +4	+4%	+$918	﹤0.01%	680
2019 Q4	$23K	Hold	103	–	–	﹤0.01%	736
2019 Q3	$17K	Hold	103	–	–	﹤0.01%	797
2019 Q2	$19K	Hold	103	–	–	﹤0.01%	739
2019 Q1	$19K	Hold	103	–	–	﹤0.01%	677
2018 Q4	$17K	Hold	103	–	–	﹤0.01%	669
2018 Q3	$20K	Hold	103	–	–	﹤0.01%	679
2018 Q2	$18K	Hold	103	–	–	﹤0.01%	702
2018 Q1	$17K	Sell	103 -3	-3%	-$490	﹤0.01%	626
2017 Q4	$16K	Buy	106 +3	+3%	+$444	﹤0.01%	581
2017 Q3	$16K	Buy	+103	New	+$15.5K	﹤0.01%	466

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Wealthcare Advisory Partners's VRTX Position: Q2 2026 in Review

Wealthcare Advisory Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 4.4% in Q2 2026, selling an estimated $95.3K and leaving 4,627 shares worth $2.3M. The position accounts for 0.04% of the portfolio, ranked #327.

Wealthcare Advisory Partners first reported a position in VRTX in Q3 2017 and has held it in 33 quarters since. The position peaked at $2.38M in Q4 2025. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Wealthcare Advisory Partners held 4,627 shares of Vertex Pharmaceuticals worth $2.3M as of Q2 2026.
Wealthcare Advisory Partners sold 215 Vertex Pharmaceuticals shares in Q2 2026, an estimated $95.3K.
Vertex Pharmaceuticals made up 0.04% of Wealthcare Advisory Partners's portfolio in Q2 2026, its #327 holding.
Wealthcare Advisory Partners first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 33 quarters since.
Wealthcare Advisory Partners's Vertex Pharmaceuticals position peaked at $2.38M in Q4 2025.
334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2026, filed 9 Jul 2026.